Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology News
  • Baricitinib effective...

Baricitinib effective in cutaneous manifestations of dermatomyositis

Written By : Dr Manoj Kumar Nayak |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-12-30T09:45:47+05:30  |  Updated On 30 Dec 2022 3:19 PM IST
Baricitinib effective in cutaneous manifestations of dermatomyositis
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Baricitinibeffective in cutaneous manifestations of dermatomyositis

Dermatomyositis(DM) is a rare autoimmune collagen vascular disease with cutaneous and systemicinvolvement significantly impairing quality of life. Induction of type Iinterferon (IFN) and its IFN-stimulated genes (ISGs) was discovered in patients'blood, muscle and skin. Current treatment options are only partially effectivein DM-associated panniculitis. Inhibiting the activation of Janus kinase(JAK)-transmitting signals of the type I IFN receptor is a valuable therapeuticoption. Recently an article showing efficacy of JAK inhibitor baricitinib in cutaneousmanifestations in juvenile DM was published in the British Journal ofDermatology.

Theprominence of type I IFN signature in DM was the basis for trial of barcitinibin 3 patients of DM. Patient1 had experienced a recurrent disease course for 25 years and was on partialremission with low-dose prednisolone (5 mg per day),methotrexate, hydroxychloroquine and adalimumab. She presentedwith a new disease flare with violaceous erythema prone to the face, collar, neckand periungual area, but normal muscle enzymes. The therapy with methotrexateand adalimumab was terminated due to an increase in liver enzymes. Thereafter,tofacitinib was started but was not well tolerated because of lactose intolerancein the patient. Therefore, the therapy was changed to baricitinib 4 mg daily.The neck, facial and periungual erythema completely regressed within 5 monthsof treatment

Patient2 had experienced anti-NXP2 antibody-positive DM with severe muscle weakness,facial and abdominal erythema and an erythematous, painful and ulceratedsclerosing plaque in the lower back that was histologically confirmed aspanniculitis. While the initial DM skin rash and muscle weakness resolved undertherapy with high-dose prednisolone, azathioprine and monthly infusions ofIVIG, the ulcerative panniculitis showed no long-term remission. Subsequently,therapy with baricitinib 4 mg daily was initiated. Concomitant medication withprednisolone 5 mg and one cycle of IVIG per month was continued. Afterinitiation of baricitinib treatment, the panniculitis improved, and resolvedwith residual scarring after 4 months. IVIG was stopped and remission wasmaintained by baricitinib treatment. Interruption of therapy for 1 month, 6months later induced an immediate flare of ulcerative panniculitis that waseffectively controlled by reinitiating baricitinib alone.

Patient3 was diagnosed with anti-MDA5 antibody-positive DM with prominent and severeskin involvement. No interstitial lung or significant muscle involvement was detected.Initial treatment consisted of prednisolone, hydroxychloroquine 200 mg andmethotrexate. Methotrexate was discontinued due to leucopenia and an abscess inthe axilla. Thereafter, treatment with baricitinib was started, resulting in resolutionof erythema and pain.

Exceptfor an outbreak of labial herpes in patient 1, therapy with baricitinib waswell tolerated and no severe side-effects were recorded. Baricitinib improvedcutaneous lesions after only 4 weeks of treatment as assessed by the CutaneousDermatomyositis Area and Severity Index and the Dermatology Life Quality Index.

Thetype I IFN signature in the patients was demonstrated by upregulation of ISGsin blood and activation of p-JAK1 and p-STAT1 (signal transducer and activatorof transcription) in the skin of patients with DM. ISGs had decreased in theblood of patients 1 month after the initiation of baricitinib treatment. Invitro treatment of whole blood from patients with DM with baricitinib resultedin significant downregulation of IFI44 and IFI27 expression and thus confirmed thereduction of ISGs by JAK inhibition.

Panniculitisis a rare cutaneous complication in DM and has been described only once inassociation with NXP2 antibodies. The condition is generally hard to treat and does not respond aswell as muscle inflammation to immunosuppressive treatment. Here we provideclinical evidence of a beneficial effect of baricitinib in combination withIVIG in this rare but severe DM skin manifestation.

Inconclusion, inhibition of the JAK pathway with baricitinib can be an effective therapeuticapproach in adult DM with cutaneous manifestations including raremanifestations such as panniculitis.

Source- Fischer K, Aringer M,Steininger J, Heil J, Beissert S, Abraham S, Günther C. Improvement ofcutaneous inflammation and panniculitis in patients with dermatomyositis by theJanus kinase inhibitor baricitinib. Br J Dermatol. 2022 Sep;187(3):432-435.doi: 10.1111/bjd.21252. Epub 2022 May 20. PMID: 35318646.

BaricitinibJAK inhibitordermatomyositisIFNIVIGBJD
Source : British Journal of Dermatology
Dr Manoj Kumar Nayak
Dr Manoj Kumar Nayak

    MBBS

    Dr Manoj Kumar Nayak has completed his M.B.B.S. from the prestigious institute Bangalore medical college and research institute, Bengaluru. He completed his M.D. Dermatology from AIIMS Rishikesh. He is actively involved in the field of dermatology with special interests in vitiligo, immunobullous disorders, psoriasis and procedural dermatology. His continued interest in academics and recent developments serves as an inspiration to work with medical dialogues.He can be contacted at editorial@medicaldialogues.in.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    View All

    Journal Club Today

    Global Omega-3 Shortage Poses Serious Health and Environmental Risks: Study

    Global Omega-3 Shortage Poses Serious Health and Environmental Risks: Study

    View All

    Health News Today

    Health Bulletin 31/May/2025

    Health Bulletin 31/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok